These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1941374)

  • 1. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies.
    Pizzo PA; Rubin M; Freifeld A; Walsh TJ
    J Pediatr; 1991 Nov; 119(5):679-94. PubMed ID: 1941374
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of fever in patients with cancer and treatment-induced neutropenia.
    Pizzo PA
    N Engl J Med; 1993 May; 328(18):1323-32. PubMed ID: 8469254
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of empiric vancomycin therapy in children with fever and neutropenia.
    Adcock KG; Akins RL; Farrington EA
    Pharmacotherapy; 1999 Nov; 19(11):1315-20. PubMed ID: 10555937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial empiric therapy for fever in neutropenia.
    Bustamante CI
    Recent Results Cancer Res; 1993; 132():45-56. PubMed ID: 8265870
    [No Abstract]   [Full Text] [Related]  

  • 5. Empiric therapy for bacterial infections in neutropenic patients.
    Klastersky J
    Cancer Treat Res; 1995; 79():101-12. PubMed ID: 8746651
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
    Dranitsaris G
    Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.
    Simon A; Gröger N; Wilkesmann A; Hasan C; Wiszniewsky G; Engelhart S; Kramer MH; Bode U; Ammann RA; Fleischhack G
    Int J Antimicrob Agents; 2006 Nov; 28(5):417-22. PubMed ID: 17046210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current considerations in the management of fever and neutropenia.
    Alexander SW; Pizzo PA
    Curr Clin Top Infect Dis; 1999; 19():160-80. PubMed ID: 10472485
    [No Abstract]   [Full Text] [Related]  

  • 10. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Febrile neutropenia in adult patients with solid tumours: a review of literature toward a rational and optimal management].
    Even C; Taillade L; Spano JP; Vignot S
    Bull Cancer; 2010 May; 97(5):547-57. PubMed ID: 20176547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric therapy for febrile neutropenia: what are the choices?
    Aoun M
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):507-15. PubMed ID: 17547514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fever and neutropenia: changing patterns of medical practice.
    Arceci RJ
    J Pediatr Hematol Oncol; 2000; 22(5):397. PubMed ID: 11037846
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antibiotic therapy of acute infection in patients with cancer].
    Fujimoto T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2914-21. PubMed ID: 3464227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
    Tam CS; O'Reilly M; Andresen D; Lingaratnam S; Kelly A; Burbury K; Turnidge J; Slavin MA; Worth LJ; Dawson L; Thursky KA;
    Intern Med J; 2011 Jan; 41(1b):90-101. PubMed ID: 21272173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of neutropenic infection: trends towards monotherapy?
    Klastersky J
    Support Care Cancer; 1997 Sep; 5(5):365-70. PubMed ID: 9322347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin in paediatric cancer patients: a feasible alternative to glycopeptides?
    Hepping N; Simon A
    Int J Antimicrob Agents; 2009 Apr; 33(4):389. PubMed ID: 19097756
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
    Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
    Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fever, neutropenia, and the second law of thermodynamics.
    Baden LR; Rubin RH
    Ann Intern Med; 2002 Jul; 137(2):123-4. PubMed ID: 12118968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.